Key Highlights
- Third-quarter 2026 net loss was USD 21.9 million, or USD 0.28 per share.
- Cash and cash equivalents were USD 203.1 million at September 30, 2026.
- Research and development expenses were USD 15.6 million, against USD 8.5 million a year earlier.
- The company plans to submit a BLA for aglatimagene in prostate cancer in mid-2027.
Candel Therapeutics (NASDAQ:CADL) reported a third-quarter 2026 net loss of USD 21.9 million, or USD 0.28 per share, against an estimate of a loss of USD 0.34 per share. The clinical-stage company, listed on the Nasdaq Global Market, develops aglatimagene besadenovec, referred to as aglatimagene, and linoserpaturev. It reported no revenue.
The filing says the company is in ongoing dialogue with the FDA regarding submission of a Biologics License Application for aglatimagene in prostate cancer. Because of timelines associated with certain assay refinement, it currently plans to submit the BLA in the middle of 2027, pending the result of that dialogue.
Operating Results
Research and development expenses were USD 15,587 thousand for the three months ended September 30, 2026, against USD 8,461 thousand a year earlier. General and administrative expenses were USD 7,394 thousand, against USD 4,746 thousand. Total operating expenses were USD 22,981 thousand, against USD 13,207 thousand, and loss from operations was the same USD 22,981 thousand, against USD 13,207 thousand.
For the nine months, Research and Development expenses were USD 45,228 thousand, against USD 19,468 thousand, and general and administrative expenses were USD 20,783 thousand, against USD 13,046 thousand. Total operating expenses were USD 66,011 thousand, against USD 32,514 thousand.
Other Income, Expense and Net Loss
Total other income, net, for the quarter was USD 1,108 thousand, against USD 1,938 thousand. Interest income was USD 1,816 thousand, against USD 953 thousand, and interest expense was USD 1,591 thousand, against USD 161 thousand. The change in Fair Value of Warrant liabilities was a gain of USD 860 thousand, against a gain of USD 1,146 thousand.
Net loss and comprehensive loss was USD 21,873 thousand, against USD 11,269 thousand, with basic and diluted net loss per share of USD 0.28, against USD 0.21. Weighted-average common shares outstanding were 77,385,453, against 54,894,347.
For the nine months, net loss was USD 69,639 thousand, or USD 0.98 per share, against USD 8,686 thousand, or USD 0.17 per share. The prior-year nine-month figure included a USD 21,718 thousand gain from the change in fair value of warrant liabilities, against a loss of USD 3,775 thousand in the current period.
Liquidity, Debt and Pipeline
As of September 30, 2026, the company had cash and cash equivalents of USD 203.1 million. Management said that, based on current plans and assumptions, including increased planned Investment in clinical development and commercialization readiness activities, it continues to project that its existing cash is sufficient for its current operating plan into the second quarter of 2028. It said it requires additional Capital to commercialize aglatimagene in early localized prostate cancer and to support enrollment and conduct of a Phase 3 trial.
The company completed its 2025 at-the-market program, having sold and issued 4,947,886 shares of common stock for total net proceeds of USD 48.5 million. Under its Loan and security agreement with Trinity Capital, the net carrying amount of the term loan was USD 47,072 thousand against total principal of USD 50,000 thousand, with principal payments scheduled from 2028 to 2030. A March 2026 amendment sets a minimum cash covenant of 67.5% of principal outstanding if market Capitalization is below USD 550 million, until the company raises at least USD 93.5 million in qualifying proceeds.
The filing also notes that in September 2026 the company presented biomarker data from its Phase 3 trial at the ASTRO 2026 Annual Meeting. After quarter end, on October 25, 2026, the board approved an amendment to the 2025 Inducement Plan that adds 1,700,000 shares, for an overall limit of 2,700,000 shares.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...